Tidsskr Nor Laegeforen. 2021 Sep 24;141(2021-13). doi: 10.4045/tidsskr.20.0981. Print 2021 Sep 28.
ABSTRACT
Monoclonal gammopathy is a frequent finding and may be associated with severe cancer such as myelomatosis and other B-cell lymphoproliferative disorders. However, the monoclonal component can also be the direct cause of serious disease, namely monoclonal gammopathy of clinical significance (MGCS). MGCS is most likely significantly underdiagnosed and is consequently also undertreated. In order to achieve a good therapeutic outcome, it is crucial that the condition is recognised at an early stage, so that treatment can be initiated before the patient has developed irreversible organ damage. Increased awareness of MCGS is therefore essential.
PMID:34596996 | DOI:10.4045/tidsskr.20.0981